CRSP250502C54000
- 0.07
- 0.000.00%
CRISPR Therapeutics Newsroom
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies
CRISPR Therapeutics AG (NASDAQ:CRSP) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
'Incoming Regulatory Tailwinds' to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities
Leerink Partners Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $60
Analysts' Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Applied Therapeutics (APLT)
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week
Express News | CRISPR Therapeutics AG : Leerink Partners Cuts Target Price to $60 From $65
Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $57
Palantir, Crispr, and Other Stocks Cathie Wood Thinks Could Emerge Strong From a Recession -- Barrons.com
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Cathie Wood Thinks These Firms Could Emerge Strong From a Recession
Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target
CRISPR Therapeutics Analyst Ratings
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know
Crispr Therapeutics Gets Orphan Drug Status for Lymphoma Treatment